ATAI News and Press, ATAI Life Sciences N.V. From 04/03/24

2024-04-03 10:47:15 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18% Seeking Alpha...

2024-04-03 08:53:52 ET More on premarket gainers & stock Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects SELLAS Life Sciences GAAP EPS of -$1.3...

2024-03-28 11:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ATAI Life Sciences (NASDAQ: ATAI ) just reported results for the fourth quarter of 2023. ATAI Life Sciences reported earnings per share of -12 cents. This was above the an...

2024-03-28 07:18:08 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18% Seeking Alpha...

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato® Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durabl...

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of response was maintained at week 4 and week 1...

University of Calgary scientists want to conduct a trial on the use of psilocybin as a treatment for alcohol use disorder (AUD). The trial will be carried out at the Hotchkiss Brain Institute and will include 128 individuals with alcohol use disorder. Each of the participants will undergo s...

Bitdeer Technologies Group (BTDR) is expected to report $0.11 for Q4 2023 BioForce Nanosciences Holdings Inc (BFNH) is expected to report for Q4 2023 Casino Guichard Perrachon ADR (CGUSY) is expected to report for quarter end 2023-12-31 Motorsport Games Inc. (MSGM) is expected to repo...

2024-03-19 08:00:07 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – March 19, 2024 – The U.S. Federal Drug Administration (FDA) has now designated psilocybin, a classical compound found in “magic mushrooms,” as a &#...

--News Direct-- atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion. Rao explained that VLS-01 is a formulation of DMT, the active component...